Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

吉非替尼 腺癌 化疗 医学 肿瘤科 内科学 肺癌 随机对照试验 肺腺癌 表皮生长因子受体 癌症
作者
Baohui Han,Bo Jin,Tianqing Chu,Yanjie Niu,Yu Dong,Jianlin Xu,Aiqing Gu,Hua Zhong,Huimin Wang,Xueyan Zhang,Chunlei Shi,Yanwei Zhang,Wei Zhang,Yuqing Lou,Lei Zhu,Jun Pei
出处
期刊:International Journal of Cancer [Wiley]
卷期号:141 (6): 1249-1256 被引量:121
标识
DOI:10.1002/ijc.30806
摘要

To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations, a head-to-head study was performed to compare chemotherapy and gefitinib in combination or with either agent alone as first-line therapy, in terms of efficacy and safety. A total of 121 untreated patients with advanced lung adenocarcinoma who harbored sensitive EGFR mutations were randomly assigned to receive gefitinib combined with pemetrexed and carboplatin, pemetrexed plus carboplatin or gefitinib alone. The progression-free survival (PFS) of patients in the combination group (17.5 months, 95% CI, 15.3–19.7) was longer than that of patients in the chemotherapy group (5.7 months, 95% CI, 5.2–6.3) or gefitinib (11.9 months, 95% CI, 9.1–14.6) group. The (hazard ratios) HRs of PFS for the combination group vs. chemotherapy and gefitinib groups were 0.16 (95% CI, 0.09–0.29, p < 0.001) and 0.48 (95% CI, 0.29–0.78, p = 0.003), respectively. The overall response rate (ORR) in the combination therapy group, chemotherapy group and the gefitinib group was 82.5%, 32.5% and 65.9%, respectively. The combinational strategy resulted in longer overall survival (OS) than chemotherapy (HR = 0.46, p = 0.016) or gefitinib (HR = 0.36, p = 0.001) alone. Our finding suggested that treatment with pemetrexed plus carboplatin combined with gefitinib could provide better survival benefits for patients with lung adenocarcinoma harboring sensitive EGFR mutations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
飘零枫叶完成签到,获得积分10
刚刚
ning完成签到,获得积分10
刚刚
潇洒的凌兰完成签到,获得积分10
刚刚
龙兰完成签到,获得积分10
1秒前
木直发布了新的文献求助10
1秒前
schen完成签到,获得积分10
2秒前
中和皇极完成签到,获得积分0
2秒前
1028181661发布了新的文献求助10
2秒前
专心搞学术完成签到,获得积分10
2秒前
Jansen完成签到,获得积分10
3秒前
whisper完成签到,获得积分10
3秒前
huyan完成签到,获得积分10
3秒前
阿瓦隆的蓝胖子完成签到,获得积分10
4秒前
dhn123完成签到,获得积分20
4秒前
车灵波完成签到 ,获得积分10
4秒前
Roche完成签到,获得积分10
4秒前
lfzw应助6789采纳,获得10
5秒前
哎呦喂完成签到,获得积分10
5秒前
挽风完成签到,获得积分10
5秒前
Junewill完成签到,获得积分10
5秒前
超A完成签到,获得积分20
5秒前
牛爷爷发布了新的文献求助10
5秒前
小二郎应助1028181661采纳,获得10
6秒前
可爱的函函应助1028181661采纳,获得10
6秒前
6秒前
善良的火完成签到 ,获得积分10
6秒前
7秒前
7秒前
英姑应助科研通管家采纳,获得10
8秒前
英姑应助科研通管家采纳,获得10
8秒前
大模型应助科研通管家采纳,获得10
8秒前
cc完成签到,获得积分20
8秒前
8秒前
Akim应助科研通管家采纳,获得10
8秒前
8秒前
8秒前
慕青应助科研通管家采纳,获得10
8秒前
8秒前
8秒前
8秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968719
求助须知:如何正确求助?哪些是违规求助? 3513608
关于积分的说明 11168681
捐赠科研通 3248960
什么是DOI,文献DOI怎么找? 1794573
邀请新用户注册赠送积分活动 875194
科研通“疑难数据库(出版商)”最低求助积分说明 804716